Biogen (NASDAQ:BIIB) Price Target Raised to $215.00 at Citigroup

Biogen (NASDAQ:BIIB) had its price objective hoisted by Citigroup from $185.00 to $215.00 in a research note issued to investors on Monday morning,Benzinga reports. Citigroup currently has a neutral rating on the biotechnology company’s stock.

Several other research analysts have also recently weighed in on the stock. Stifel Nicolaus boosted their price objective on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a report on Friday. Guggenheim lifted their target price on shares of Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research report on Monday. Canaccord Genuity Group boosted their target price on shares of Biogen from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday. Jefferies Financial Group increased their price target on Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a report on Friday, November 28th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Thirteen investment analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $206.21.

Biogen Trading Down 3.7%

Shares of NASDAQ:BIIB opened at $193.81 on Monday. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. Biogen has a 1 year low of $110.04 and a 1 year high of $202.41. The company has a market cap of $28.43 billion, a P/E ratio of 22.00, a PEG ratio of 1.70 and a beta of 0.16. The stock’s fifty day moving average price is $177.26 and its 200-day moving average price is $157.48.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.Biogen’s revenue was down 7.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Sell-side analysts expect that Biogen will post 15.83 earnings per share for the current year.

Insider Activity

In other news, insider Priya Singhal sold 748 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total value of $134,116.40. Following the completion of the sale, the insider directly owned 6,271 shares in the company, valued at $1,124,390.30. This represents a 10.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.18% of the stock is currently owned by insiders.

Institutional Trading of Biogen

Hedge funds have recently bought and sold shares of the stock. Huntington National Bank increased its position in Biogen by 7.1% in the fourth quarter. Huntington National Bank now owns 2,447 shares of the biotechnology company’s stock worth $431,000 after buying an additional 162 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Biogen by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock valued at $736,435,000 after buying an additional 130,618 shares in the last quarter. Cary Street Partners Investment Advisory LLC grew its stake in shares of Biogen by 126.6% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 247 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 138 shares during the period. Mmbg Investment Advisors CO. bought a new position in shares of Biogen during the 4th quarter valued at approximately $220,000. Finally, Allstate Corp increased its holdings in Biogen by 105.8% in the 4th quarter. Allstate Corp now owns 9,672 shares of the biotechnology company’s stock worth $1,702,000 after acquiring an additional 4,972 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance: Biogen reported fourth‑quarter and FY results ahead of expectations, prompting analysts to raise forecasts and price targets — a direct earnings-driven positive catalyst. Biogen Posts Q4 Beat, Analysts Raise Price Targets
• Positive Sentiment: Regulatory progress for Leqembi: A biologics license application for a subcutaneous formulation of Leqembi was designated for priority review — this could expand prescribing convenience and bolster long‑term franchise value. Biologics License Application for Subcutaneous LEQEMBI Designated for Priority Review
• Positive Sentiment: Geographic expansion: Reports that China fast‑tracked at‑home use of Leqembi add another potential growth market for the Alzheimer’s franchise. Biogen stock to pop again? China fast-tracks Leqembi
• Positive Sentiment: Big analyst upgrades: RBC raised its price target to $233 (Outperform) and HC Wainwright raised its target to $228 (Buy), both signalling double‑digit upside from current levels and reflecting confidence in Leqembi and cash‑flow prospects. RBC Raises Price Target on Biogen to $233
• Neutral Sentiment: Mixed/neutral analyst stances: Several shops (Citigroup, Piper Sandler, Wedbush, Truist) nudged price targets higher but kept Neutral/Hold ratings, leaving investor guidance mixed. Analyst Price Target Moves (Citigroup, Piper, Wedbush, Truist)
• Negative Sentiment: Franchise pressure and execution risk: Analysis points to MS‑franchise weakness and near‑term growth limits, which keep some analysts cautious despite the Alzheimer’s upside. Biogen FY25 Earnings: Stable EPS Amid MS Franchise Pressure

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.